Did You Know Ab Initio Leads the Way in Developing Inhaled and Nasal Biologics?: Meet with our CSO, YY at DDL 2024
Meet with CSO YY and the team to discuss how we can help you develop your next inhaled biological.
At Ab Initio Pharma, we specialise in helping you develop orally inhaled and nasal drug products (OINDPs) containing biologics such as RNA, proteins, peptides, and oligonucleotides. Whether you’re working on groundbreaking gene therapies or next-generation therapeutic formulations, our expertise ensures innovative, effective solutions tailored to your needs.
Want to learn more Explore our work at DDL 2024?
Hear from our CSO how we developed advanced intranasal RNA therapies:
Dr. Hui Xin Ong (YY): Join YY's talk, where she’ll present a case study on our intranasal RNA development program in partnership with Tetratherix.
Session: Gene Therapy and Biologics for the Lungs - December 11, 2024 | 4:30 PM
Check out our Poster Presentation on inhaled oligonucleotides:
Discover how we’re developed clinical trial ready orally inhaled oligonucleotide therapies with Rage Therapeutics..
Learn more - from bench to trial:
Visit us at Booth #210 during the conference to learn how our cutting-edge solutions in biologic drug delivery can bring your products to life. Let’s collaborate to create therapies that make a difference!
#DDL2024 #Biologics #InhaledDrugDelivery #Innovation
